about
Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant womenWheeze as an adverse event in pediatric vaccine and drug randomized controlled trials: A systematic reviewCombining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?A systematic review of adverse events following immunization during pregnancy and the newborn periodObstetrical and neonatal case definitions for immunization safety dataAdverse events following immunization: perception and evidencePediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP ProjectGuillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in EuropePandemic influenza vaccine & narcolepsy: simulations on the potential impact of bias.Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in EuropeSafety of pandemic H1N1 vaccines in children and adolescents.The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns.International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines.Persistent crying in infants and children as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation.Narcolepsy as an adverse event following immunization: case definition and guidelines for data collection, analysis and presentation.A systematic review of safety data reporting in clinical trials of vaccines against malaria, tuberculosis, and human immunodeficiency virus.The Brighton Collaboration: enhancing comparability of vaccine safety data.Pediatric drug safety signal detection: a new drug-event reference set for performance testing of data-mining methods and systems.Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation.Hypotonic-Hyporesponsive Episode (HHE) as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation.Reporting of vaccine safety data in publications: systematic review.Vasculitic peripheral neuropathy: Case definition and guidelines for collection, analysis, and presentation of immunisation safety data.Unexplained sudden death, including sudden infant death syndrome (SIDS), in the first and second years of life: case definition and guidelines for collection, analysis, and presentation of immunization safety data.Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data.Thrombocytopenia: case definition and guidelines for collection, analysis, and presentation of immunization safety data.Hypotonic-hyporesponsive episode (HHE) as an adverse event following immunization in early childhood: case definition and guidelines for data collection, analysis, and presentation.Aseptic meningitis: case definition and guidelines for collection, analysis and presentation of immunization safety data.Systemic Lupus Erythematosus: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.Kawasaki disease and immunisation: Standardised case definition & guidelines for data collection, analysis.Single organ cutaneous vasculitis: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.IgA vasculitis (Henoch-Schönlein): Case definition andguidelines for data collection, analysis, and presentation of immunisation safety data.Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies.Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems.A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark.The Global Vaccine Safety Initiative: enhancing vaccine pharmacovigilance capacity at country level.Diagnosis of acute haematogenous osteomyelitis and septic arthritis: 20 years experience at the University Children's Hospital Basel.Procalcitonin guidance to reduce antibiotic treatment of lower respiratory tract infection in children and adolescents (ProPAED): a randomized controlled trial.Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases.Template protocol for clinical trials investigating vaccines--focus on safety elementsImmunisation of premature infants.
P50
Q26250281-FE218650-ED9C-4FCF-B2FC-B9B3DBDF9690Q26796334-33C0621A-9332-4E44-AB54-D3A69B82E86CQ26996499-35B45722-AEB7-4ED6-930E-0D9B8C65B879Q28081836-4AC7E921-BE74-46BE-81EC-8BD1DEFF5C34Q28119706-0F464889-699B-461D-B59D-69CFF713008EQ28300118-DF11A9BC-D7D8-4E41-9238-772A886EFD49Q28548499-A2F69067-8838-4D83-8B20-34FDD6F864BBQ30357675-12FA84E4-AFDD-4936-B67E-DD8466524D4FQ30385564-F277B8AD-FC92-4DAD-92F3-81873D45E38FQ30404728-C55B3CED-88D5-4335-AB30-8D7B5EA04295Q30405733-ED764181-2F88-467B-9584-3540A4A51E47Q30424863-A6988E98-8453-4F16-80C1-C0A40703EC8DQ30431960-19DE553A-A369-49A2-AE3F-E46DFA16CBA0Q30540817-70EEB90B-173A-4534-9A82-3B30B2AE6E07Q30582000-A39E8A3A-8292-411D-B64B-866CE58FD6C8Q30587522-F22573BC-B15D-4F01-8BE8-35D9F2029979Q30804369-39B76CE9-262C-4B0C-883B-5454686C400BQ30889974-349C75A3-4405-4DE6-81DF-34658F013968Q30890102-A308D6C5-D90B-4F9E-883F-565AAD2D2FDFQ30890127-3E4023C7-16C0-4748-B7B0-30CF1B819662Q30961908-F4B5ADCB-BF6B-47ED-9EC8-19CC7324D68CQ31031526-86DA3FFA-3BE0-40B9-97AC-241516765935Q31108130-F9F033C7-1949-409D-A0AE-D819A6E04269Q31109981-1DEC8D1E-F391-4213-AB47-6E4558CC522BQ31112245-2D4BE022-0AF1-43B9-A45E-3A311D1524B9Q31114165-0C5424CD-0245-4939-BC32-AFE509F0959EQ31116047-1197B4EE-A62F-4E46-87F2-4BD8910B7DEBQ31141083-7CA0C02C-3466-48F9-8EB2-04711500418EQ31143319-431E5697-5705-4F42-9108-1D24566053B0Q31151768-E7F77E40-5DB6-46A5-888B-2B6A027ACFCAQ31151982-A111DCC5-B465-491A-A875-E58C906D6F4AQ33389704-6ACEF8FA-C9AB-4ED6-A195-9EB3B88A9F46Q33390588-F03C51DC-B3EF-4562-B9B7-C0D3649C0D06Q33395909-582CD804-0176-4E13-91E5-B3E2902EF8D9Q34399603-4E9BE2B2-659A-4212-8B68-FCC82EC3113BQ34483946-AB2419C8-0F30-4D58-9A94-8C0C440462A6Q34924079-D81006D7-EB47-4402-80B0-8E79C78B8A26Q35782657-27B2BE3C-AC9E-4492-AF3A-8AD28A5F6406Q36100736-97C16D55-EB50-4BD7-8DF2-43C6755E7DE6Q36153379-696A7AB3-C4CC-418D-8D6A-068D3DCFABA9
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jan Bonhoeffer
@ast
Jan Bonhoeffer
@en
Jan Bonhoeffer
@es
Jan Bonhoeffer
@nl
Jan Bonhoeffer
@sl
type
label
Jan Bonhoeffer
@ast
Jan Bonhoeffer
@en
Jan Bonhoeffer
@es
Jan Bonhoeffer
@nl
Jan Bonhoeffer
@sl
prefLabel
Jan Bonhoeffer
@ast
Jan Bonhoeffer
@en
Jan Bonhoeffer
@es
Jan Bonhoeffer
@nl
Jan Bonhoeffer
@sl
P108
P106
P31
P496
0000-0001-9704-8315